In 2006 Genentech acquired
Tanox in its first acquisition deal. Tanox had started developing
Xolair and development was completed in collaboration with Novartis and Genentech; the acquisition allowed Genentech to keep more of the revenue.[14]
In March 2009 Roche acquired Genentech by buying shares it didn't already control for approximately $46.8 billion.[15][16][17]
In July 2014, Genentech/Roche acquired Seragon for its pipeline of small-molecule cancer drug candidates for $725 million cash upfront, with an additional $1 billion of payments dependent on successful development of products in Seragon's pipeline.[18]
Research
Genentech is a pioneering research-driven
biotechnology company[13] that has continued to conduct R&D internally as well as through collaborations.[19][20]
Genentech's research collaborations include:
In 2008 Genentech entered into a collaboration with Roche and its subsidiary GlycArt to develop
obinutuzumab.[21]
In February 2010 Genentech entered into a collaboration with
University of California, San Francisco after having worked with them in about fifteen other collaborations, this time to collaborate on small molecule
drug discovery in neurology.[22]
In October 2014 Genentech paid $150M upfront to collaborate with Iowa-based NewLink Genetics on
checkpoint inhibitors.[23]
In June 2015 it entered into a wide-ranging partnership with
The Data Incubator to help train and hire the next generation of data scientists at the company.[24]
In January 2015 it signed a $60M deal with
23andMe that gave Genentech access to the genomic and patient-reported data held by 23andMe.[25]
In October 2015 it started a collaboration with Nimbus Therapeutics to develop leads from Nimbus'
in silico drug discovery platform.[26]
In June 2016 Genentech partnered Epizyme to conduct clinical trials exploring whether Epizyme's EZH2 inhibitor
tazemetostat would be synergistic with Genentech's
atezolizumab.[27]
In August 2016, the company began a collaboration with Carmot Therapeutics in which Carmot will
discover new candidates and Genentech will
develop them.[28]
In December 2006, Genentech sold its
Porriño,
Spain, facility to
Lonza and acquired an exclusive right to purchase Lonza's mammalian cell culture manufacturing facility under construction in
Singapore. In June 2007, Genentech began the construction and development of an E. coli manufacturing facility, also in Singapore, for the worldwide production of
Lucentis (
ranibizumab injection) bulk drug substance.[citation needed]
In 2023, the company announced plans to close down its manufacturing facility in South San Francisco, while expanding its manufacturing capabilities in Oceanside.[31][32]
Public-private engagement
Political lobbying
Genentech is a donor to the Center for Health Care Strategies, a non-governmental organization that lobbies the
United States Government on issues related to
Medicaid.[33]
Genentech Inc Political Action Committee
Genentech Inc Political Action Committee is a U.S. Federal
Political Action Committee (PAC), created to "aggregate contributions from members or employees and their families to donate to candidates for federal office".[34]
Controversy
Disputes
In November 1999, Genentech agreed to pay the
University of California, San Francisco $200 million to settle a nine-year-old patent dispute. In 1990, UCSF sued Genentech for $400 million in compensation for alleged theft of technology developed at the university and covered by a 1982 patent.[citation needed] Genentech claimed that they developed
Protropin (recombinant
somatotropin/human growth hormone), independently of UCSF. A jury ruled that the university's patent was valid in July 1999, but wasn't able to decide whether Protropin was based upon UCSF research or not. Protropin, a drug used to treat
dwarfism, was Genentech's first marketed drug and its $2 billion in sales has contributed greatly to its position as an industry leader.[citation needed] The settlement was to be divided as follows: $30 million to the
University of California General Fund, $85 million to the three inventors and two collaborating scientists, $50 million towards a new teaching and research campus for UCSF, and $35 million to support university-wide research.[35]
In 2009, The New York Times reported that Genentech's talking points on
health care reform appeared verbatim in the official statements of several Members of
Congress during the national health care reform debate.[36] Two
U.S. Representatives,
Joe Wilson and
Blaine Luetkemeyer, both issued the same written statements: "One of the reasons I have long supported the U.S. biotechnology industry is that it is a homegrown success story that has been an engine of job creation in this country. Unfortunately, many of the largest companies that would seek to enter the biosimilar market have made their money by outsourcing their research to foreign countries like India." The statement was originally drafted by lobbyists for Genentech.
Products timeline
1982: Synthetic "human"
insulin approved by the
U.S. Food and Drug Administration (FDA), partnered with insulin manufacturer
Eli Lilly and Company, who shepherded the product through the FDA approval process. The product (
Humulin) was licensed to and manufactured by Lilly, and was the first-ever approved genetically engineered human therapeutic.
1993:
Pulmozyme (dornase alfa): Inhalation treatment for children and young adults with
cystic fibrosis—recombinant
DNAse.
1997:
Rituxan (rituximab): Treatment for specific kinds of
non-Hodgkin's lymphomas. In 2006, also approved for rheumatoid arthritis.
1998:
Herceptin (trastuzumab): Treatment for
metastatic breast cancer patients with tumors that overexpress the
HER2 gene. Recently approved for adjuvant therapy for breast cancer. FDA also recently approved Trastuzumab for metastatic gastric cancer with HER2 receptor site positive.
2003:
Xolair (omalizumab): Subcutaneous injection for moderate to severe persistent
asthma.
2003:
Raptiva (efalizumab): Antibody designed to block the activation and reactivation of
T cells that lead to the development of
psoriasis. Developed in partnership with
XOMA. In 2009, voluntary U.S. market withdrawal after reports of
progressive multifocal leukoencephalopathy.
2004:
Avastin (bevacizumab): Anti-VEGF
monoclonal antibody for the treatment of metastatic cancer of the
colon or
rectum. In 2006, also approved for locally advanced, recurrent or metastatic
non-small cell lung cancer. In 2008, accelerated approval was granted for Avastin in combination with chemotherapy for previously untreated advanced HER2-negative breast cancer. In 2009, Avastin gained its fifth approval for treatment of
glioblastoma multiforme, and sixth approval for the treatment of metastatic
renal cell carcinoma. It was most publicized for its approval in advanced breast cancer treatment, but the FDA approval for breast cancer treatment was subsequently revoked in November 2011.
2004:
Tarceva (erlotinib): Treatment for patients with locally advanced or metastatic non-small cell lung cancer, and pancreatic cancer.
2006:
Lucentis (ranibizumab injection): Treatment of neovascular (wet) age-related macular degeneration (AMD). The FDA approved LUCENTIS after a Priority Review (six-month). Genentech started shipping product on June 30, 2006, the day the product was approved.
2010:
Actemra (tocilizumab): The first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody approved to treat rheumatoid arthritis (RA).
2012:
Erivedge (vismodegib): Treatment for advanced
basal-cell carcinoma (BCC). A small molecule inhibitor that targets a key protein in the
Hedgehog signaling pathway. This is the first approved therapy for advanced BCC.
2012:
Perjeta (pertuzumab): For use in combination with Herceptin (trastuzumab) and
docetaxel chemotherapy for the treatment of patients with previously untreated HER2-positive metastatic breast cancer.
2013:
Kadcyla (ado-trastuzumab emtansine): The first Genentech antibody-drug conjugate (ADC) to receive FDA approval. It consists of trastuzumab (Herceptin) linked to a cytotoxic agent mertansine (DM1), used in the treatment of HER2-positive metastatic breast cancer.
2013:
Gazyva (obinutuzumab): For use in combination with chlorambucil to treat patients with previously untreated
chronic lymphocytic leukemia (CLL). Gazyva is the first drug with
breakthrough therapy designation to receive FDA approval.
2014:
Esbriet (pirfenidone): An anti-fibrotic drug for the treatment of idiopathic pulmonary fibrosis (IPF). Developed by Intermune, Inc.
2015:
Cotellic (cobimetinib): For use in combination with ZELBORAF (vemurafenib), to treat
metastatic melanoma caused by
BRAF mutation.
2015:
Alecensa (alectinib): Treatment for non-small cell lung cancer (NSCLC).
2016:
Venclexta (venetoclax): Treatment for patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy.
2016:
Tecentriq (atezolizumab): First-in-class anti-PD-L1 antibody for the treatment of advanced bladder cancer or metastatic non-small cell lung cancer (NSCLC), both after failure of platinum-based chemotherapy. Tecentriq was granted accelerated approval for its advanced bladder cancer indication due to promising phase II results.
2017:
Ocrevus (ocrelizumab): The first FDA-approved therapy that treats both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS). The PPMS form of the disease previously had no approved treatments.
2018:
Xofluza (Baloxavir marboxil): Antiviral medication for treatment of influenza A and influenza B. Developed by
Shionogi.
2019:
Polivy (Polatuzumab vedotin-piiq): Treatment of diffuse large B-cell lymphoma when used in combination with bendamustine and rituximab.
Diversity and inclusion efforts
Led by Chief Diversity Officer, Quita Beeler Highsmith, Genentech also co-hosts the Health Equity Symposium, a collaboration with healthcare institutions and community organizations to address inequities among diverse populations.[37]
In 2022, Genentech won the following awards for their diversity and inclusion efforts:
Forbes named Genentech one of “America's Best Employers for Diversity”[38]
Forbes named Genentech one of “America’s Best Large Employers”[39]
Human Rights Campaign Diversity scoring Genentech 100 on the “Corporate Equality Index”[40]
Awards and recognitions
Fortune Magazine has listed Genentech on its "100 Best Companies To Work For" for 22 consecutive years, with a number one ranking on its 2006 list. The ranking has varied from number 1 to number 80 throughout the years.[41] The ranking is based on anonymous employee responses to a survey as well as an evaluation of the company's policies and culture.
Genentech was named one of the 100 Best Companies for Working Mothers in 2004, 2006-8 and 2010–11 by Working Mother Magazine.[42]
It was named as one of the 100 best corporate citizens 2006 by the Business Ethics Magazine. The company participates in various policy and civic leadership groups, such as TechNet,[43] and sponsors independent third-party research and publications, such as the journal Nature.[44]
Genentech was named Top Employer by Science Magazine on October 7, 2010, where it has been recognized for nine consecutive years.[45]
In March 2008, Genentech was named Most Admired Pharmaceutical Company by Fortune for the second consecutive year.
In July 2010, Genentech was named on the "Top 100 Best Places to Work in IT" list by ComputerWorld magazine.[46]
^Genentech.
"Corporate Overview". Archived from
the original on April 18, 2012. Genentech was founded by venture capitalist Robert A. Swanson and biochemist Dr. Herbert W. Boyer. After a meeting in 1976, the two decided to start a biotechnology company, Genentech. Although the two confidently assert that it was the first biotech company, others clearly came before, including
Cetus Corporation which was founded in 1971.
^"In January 1976, 28-year-old venture capitalist Robert Swanson entered the picture. A successful
cold-call to Boyer's lab led to a couple of beers—and an agreement to start a pharmaceutical company. Investing $500 each, they capitalized a new business, Genentech, to seek practical uses for Boyer and Cohen's engineered proteins. Swanson raised money for staff and labs..."
"Who made America? Herbert Boyer".
PBS.
Archived from the original on June 20, 2012. Retrieved August 28, 2017.
^Itakura, K.; Hirose, T.; Crea, R.; Riggs, A. D.; Heyneker, H. L.; Bolivar, F.; Boyer, H. W. (1977). "Expression in Escherichia coli of a chemically synthesized gene for the hormone somatostatin". Science. 198 (4321): 1056–1063.
Bibcode:
1977Sci...198.1056I.
doi:
10.1126/science.412251.
PMID412251.
^"Carmot to Use Lead-Identification Technology in Collab with Genentech". News: Discovery & Development. Genetic Engineering & Biotechnology News (Paper). 36 (14): 17. August 2016.